Slingshot Insights

Catalyst

Slingshot members are tracking this event:

Data for Phase 2 MONARCH 1 Trial of Abemaciclib Expected mid-2016

Source Link:: http://seekingalpha.com/article/3844696-eli-lilly-and-co-lly-john-c-lechleiter-q4-2015-results-earnings-call-transcript?part=single

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

LLY

100%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details Data from the phase 2 Monarch 1 trial of abemaciclib as a single-agent is expected mid-2016. The trial studies abemaciclib for the treatment of squamous non-small cell lung cancer.

http://seekingalpha....

Additional Relevant Details we look forward to receiving the final MONARCH 2 results in the first half of 2017

http://lilly.mediaro...

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Jun 03, 2016

Occurred Source:

https://investor.lilly.com/releasedetail.cfm?releaseid=974274

Related Projects

Don’t see a project related to the catalyst you care about?

Related Keywords Monarch 1 Study, Phase 2 Trial, Abemaciclib, Single-agent, Non-small Cell Lung Cancer